However, the presence of this association also in placebo-treated patients and the persistent beneficial effect of SGLT2 inhibitors across the BMI range indicate that the weight loss in empagliflozin- and dapagliflozin-treated patients is not related to the observed obesity paradox [8]. The gene discussed is SLC5A2; the disease is obesity due to melanocortin 4 receptor deficiency.